Moderna, Inc. (FRA:0QF)
Germany
· Delayed Price · Currency is EUR | Market Cap | 10.52B |
| Revenue (ttm) | 2.94B |
| Net Income (ttm) | -3.11B |
| Shares Out | n/a |
| EPS (ttm) | -8.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 75 |
| Average Volume | 39,984 |
| Open | 27.14 |
| Previous Close | 27.44 |
| Day's Range | 27.04 - 27.14 |
| 52-Week Range | 20.59 - 115.76 |
| Beta | n/a |
| RSI | 61.04 |
| Earnings Date | Jul 31, 2025 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial numbers in USD Financial StatementsNews
Moderna wins full FDA approval for COVID shot in children
Moderna gets full US approval for COVID vaccine in children 6 months and older
The U.S. Food and Drug Administration has granted full approval for Moderna's COVID-19 vaccine, Spikevax, in children aged 6 months through 11 years who are at an increased risk of the disease, the co...
Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine, Spikevax, in Children Aged 6 Months Through 11 Years at Increased Risk for COVID-19 Disease
Spikevax is now approved for all adults aged 65 years and older, and individuals aged 6 months through 64 years at increased risk for COVID-19 disease CAMBRIDGE, MA / ACCESS Newswire / July 10, 2025 /...
Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine, Spikevax, in Children Aged 6 Months Through 11 Years at Increased Risk for COVID-19 Disease
Spikevax is now approved for all adults aged 65 years and older, and individuals aged 6 months through 64 years at increased risk for COVID-19 disease CAMBRIDGE, MA / ACCESS Newswire / July 10, 2025 /...
Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win
Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents, in the latest round of a long-run...
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2221296112-bbea82ade567435889902f6efb75df92.jpg)
S&P 500 Gains & Losses Today: FICO Shares Plummet; Moderna Stock Rises
The S&P 500 fell 0.1% on Tuesday, July 8, 2025, after President Trump extended the deadline for "reciprocal" tariffs and discussed a 50% levy on imported copper.
US stock market close: A narrow range, Russell 2000 bounces back
Closing changes: S&P 500 -0.1% Nasdaq Composite flat Russell 2000 +0.7% DJIA -0.4% Toronto TSX Comp -0.5% It was mostly flat in the world of equities but the Russell 2000 bounced nicely after a harsh ...
Moderna stock rallies on HHS lawsuit news: analyst says negative sentiment reversing
Shares of Moderna surged 9.5% on Tuesday to $32.75 in a notable reversal of recent bearish sentiment, buoyed by legal developments and renewed investor focus on the company's potential vaccine pipelin...
Moderna Stock Is Climbing. It Has Been a Tumultuous Few Days for Pharma.
MRNY: Poor Performance Due To Moderna's Decline
Moderna (MRNA) Surges Over 10% Amid Strong Healthcare Sector Performance
Moderna (MRNA) Surges Over 10% Amid Strong Healthcare Sector Performance
Where Will Moderna Be in 10 Years?
Why Moderna Stock Was So Healthy This Week
RFK Jr. Influence Evident As Vaccine Chief Overrules Scientists, Limits COVID-19 Vaccine Approval
Dr. Vinay Prasad , the U.S. Food and Drug Administration’s (FDA) top vaccine official, overruled agency scientists to limit approval of two COVID-19 vaccines, despite internal recommendations to clear...
RFK Jr.‘s top FDA vaccine official restricts 2 COVID vaccine approvals against advice of agency scientists
The new memos from the FDA show how the agency’s vaccine chief, Dr. Vinay Prasad, personally intervened to place restrictions on COVID shots from vaccine makers Novavax and Moderna.
Record closes again for the S&P and Nasdaq
The S&P and NASDAQ index both rose today and each closed at record highs for the third time in the last 3 days. The hopes for more trade deals after a favorable deal by the US with Vietnam gave stocks...
RFK Jr. Just Did The Unexpected. He Helped Moderna.
Moderna stock popped Wednesday after the CDC recommended the company's RSV vaccine for at-risk adults in their 50s.
Experimental Moderna flu shot more effective than approved vaccine, company says
Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the company’s mRNA-1010 flu vaccine’s efficacy was nearly 27 percent higher for ad...
Top Stock Movers Now: Hewlett Packard Enterprise, Moderna, Tesla, and More
U.S. equities gained at midday, with the S&P 500 and Nasdaq adding to their all-time highs, on optimism about more U.S. trade deals. The Dow Jones Industrial Average was up as well.
Moderna Shares Jump With Positive Test Results for MRNA Flu Vaccine
The biotechnology company's messenger RNA flu vaccine candidate showed positive results in a late-stage trial.
Did Down-And-Out Moderna Just Unlock The Key To Its Future Profitability?
Moderna stock veered higher Monday after its flu shot proved to be as effective as older technology in a final-phase study.
Moderna reports effective results from influenza vaccine trial
Moderna's mRNA Flu Vaccine Outperforms Standard Shots
Moderna's mRNA flu vaccine showed 26.6% better efficacy ... Full story available on Benzinga.com
Stocks making the biggest moves premarket: Meta, Moderna, Hewlett Packard Enterprise, Juniper Networks and more
These are the stocks posting the largest moves in early trading.
Moderna's influenza vaccine superior to licensed shot in study
Moderna said its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose seasonal flu shot in adults aged 50 years and older in a late-stage study.